Area 2 is made up of 6 research lines, with one group per line. Its general objectives are: the design, synthesis and characterisation of new compounds with potential neuroprotection effects in neurodegenerative disease and cerebrovascular accidents; the search for biomarkers for early diagnosis, the study of disease progression and treatment response; the characterisation of drugs in preclinical trials in animal models and in human clinical trials; and the expansion of knowledge of affective disorders in the population, studying risk factors, clinical evolution and treatment response, with the aim of improving the population’s mental health.
Dr José Luis Ayuso Mateos
ADVANCED THERAPY AND PERSONALISED MEDICINE.
Area 3 is made up of 8 research lines and 18 research groups. Among their general objectives are: the identification of biomarkers that allow prognosis and/or treatment response to be predicted when treating inflammatory, infectious or tumour-based diseases; optimisation of biological treatments through identification of biomarkers that predict treatment response; the identification of new drugs and/or treatment targets; and the search for new treatment and improvements in treatment efficacy and safety and management of treatment effects on patient quality of life.
Dr Isidoro González Álvaro